Eli Lilly and Co

Quantli Newsdesk

· 2 days ago

Eli Lilly's oral obesity pill Foundayo saw its prescriber base expand from 8,000 to 36,000 doctors in one quarter, signaling strong commercial momentum for the only oral GLP-1 approved for anytime dosing. The uptake comes as Lilly already holds approximately 60% of U.S. obesity prescriptions and raised its 2026 revenue guidance to $85–87 billion. Analysts see the rapid adoption reinforcing Lilly's dominance in the metabolic health market.

Quantli Newsdesk

· 7 days ago

Eli Lilly filed six lawsuits against U.S. entities selling unapproved versions of retatrutide, an experimental obesity drug not yet approved by any regulator. The company has referred over 200 individuals and entities to federal and state authorities and flagged more than 14,000 online listings. Poison center reports show exposures averaging about 95 cases per month in early 2026, up 265% from late 2025.

Quantli Newsdesk

· 15 days ago

Bank of America is spending more than $250 million annually on GLP-1 medications like Ozempic and Wegovy for its employees, up from zero four years ago. The investment represents about 13% of the bank's $2 billion healthcare budget and reflects a strategic bet on long-term employee health. While many employers limit coverage due to high costs, Bank of America combines medication access with health coaching programs.